612 related articles for article (PubMed ID: 25261844)
1. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
[TBL] [Abstract][Full Text] [Related]
2. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC
Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
[TBL] [Abstract][Full Text] [Related]
3. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results.
Yamazaki T; Koizumi H; Yamagishi T; Kinoshita S
Ophthalmology; 2012 Aug; 119(8):1621-7. PubMed ID: 22551738
[TBL] [Abstract][Full Text] [Related]
4. Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema.
Sonoda S; Sakamoto T; Yamashita T; Otsuka H; Shirasawa M; Kakiuchi N; Uchino E; Terasaki H; Kawano H
Invest Ophthalmol Vis Sci; 2014 Jun; 55(6):3979-85. PubMed ID: 24906857
[TBL] [Abstract][Full Text] [Related]
5. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
6. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-vascular endothelial growth factor therapy on choroidal thickness in diabetic macular edema.
Yiu G; Manjunath V; Chiu SJ; Farsiu S; Mahmoud TH
Am J Ophthalmol; 2014 Oct; 158(4):745-751.e2. PubMed ID: 24952275
[TBL] [Abstract][Full Text] [Related]
8. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
9. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.
Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T
Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088
[TBL] [Abstract][Full Text] [Related]
11. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization.
Ahn SJ; Woo SJ; Kim KE; Park KH
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema.
Okamoto M; Yamashita M; Ogata N
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):885-892. PubMed ID: 29492689
[TBL] [Abstract][Full Text] [Related]
13. Subfoveal choroidal thickness change after intravitreal ranibizumab for idiopathic choroidal neovascularization.
Cao XS; Peng XY; You QS; Zhang YP; Jonas JB
Retina; 2014 Aug; 34(8):1554-9. PubMed ID: 24667570
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
15. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy.
Kim H; Lee K; Lee CS; Byeon SH; Lee SC
Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710
[TBL] [Abstract][Full Text] [Related]
17. Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion.
Rayess N; Rahimy E; Ying GS; Pefkianaki M; Franklin J; Regillo CD; Ho AC; Hsu J
Am J Ophthalmol; 2016 Nov; 171():47-52. PubMed ID: 27567889
[TBL] [Abstract][Full Text] [Related]
18. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema.
Ozturk BT; Kerimoglu H; Bozkurt B; Okudan S
J Ocul Pharmacol Ther; 2011 Aug; 27(4):373-7. PubMed ID: 21631366
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravitreal anti-VEGF on choroidal thickness in patients with diabetic macular edema using spectral domain OCT.
Kniggendorf VF; Novais EA; Kniggendorf SL; Xavier C; Cole ED; Regatieri CV
Arq Bras Oftalmol; 2016; 79(3):155-8. PubMed ID: 27463625
[TBL] [Abstract][Full Text] [Related]
20. Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age-related macular degeneration and diabetic macular edema.
Ünlü C; Erdogan G; Gunay BO; Kardes E; Akcay BI; Ergin A
Int Ophthalmol; 2017 Feb; 37(1):147-158. PubMed ID: 27154721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
